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Aims: To investigate the efficacy and safety of insulin glargine 300 U/mL (Gla-300) vs insulin
glargine 100 U/mL (Gla-100) over 12 months in a patient-level meta-analysis, using data from
the EDITION studies in people with type 2 diabetes (T2DM).
Methods: EDITION 1, 2 and 3 were multicentre, randomized, open-label, 2-arm, parallel-group,
treat-to-target phase IIIa studies. Similar study designs and endpoints enabled a meta-analysis
to be conducted.
Results: Reductions in glycated haemoglobin (HbA1c) were better sustained over
12 months with Gla-300 than with Gla-100 (least squares [LS] mean difference in change
from baseline: −0.10 % [95% confidence interval {CI} −0.18 to −0.02] or −1.09 mmol/mol
[95% CI −2.01 to −0.20]; P = .0174). Risk of confirmed (≤3.9 mmol/L) or severe hypogly-
caemia was 15% lower with Gla-300 vs Gla-100 at night (relative risk 0.85 [95% CI 0.77–
0.92]) and 6% lower at any time of day (relative risk 0.94 [95% CI 0.90–0.98]). Rates of
hypoglycaemia were 18% lower with Gla-300 vs Gla-100 at night (rate ratio 0.82 [95% CI
0.67–0.99]), but comparable at any time of day. HbA1c <7.0 % without nocturnal hypogly-
caemia was achieved by 24% more participants with Gla-300 than with Gla-100 (relative
risk 1.24 [95% CI 1.03–1.50]). Severe hypoglycaemia was rare; in both treatment groups
the incidence of events at any time of day was ≤3.6%, while rates were ≤0.08 events per
participant-year.
Conclusions: In a broad population of people with T2DM over 12 months, use of Gla-300
provided more sustained glycaemic control and significantly lower hypoglycaemia risk at night
and at any time of day compared with Gla-100.
KEYWORDS
glycaemic control, hypoglycaemia, insulin analogues, meta-analysis, phase III study, type
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1 | INTRODUCTION
Insulin is recommended for the management of type 2 diabetes
(T2DM) once glycaemic targets can no longer be achieved using other
antihyperglycaemic agents.1 After the initiation of insulin therapy,
factors such as hypoglycaemia may reduce adherence to insulin and
compromise glycaemic control.2,3 Currently, there is little evidence
from studies in people with T2DM that lowering of hypoglycaemia
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risk with newer insulin analogues, such as insulin glargine 300 U/mL
(Gla-300), is accompanied by better glycaemic control when com-
pared with insulin glargine 100 U/mL (Gla-100).
Gla-300 has been shown to have more stable pharmacokinetic
(PK) and pharmacodynamic (PD) profiles than Gla-100, with a longer
duration of action and less variable 24-hour glucose profiles.4,5 The
efficacy and safety of Gla-300 have been compared with those of
Gla-100 in the phase III EDITION programme across a broad popula-
tion of people with T2DM and type 1 diabetes (T1DM).6–11 A meta-
analysis of patient-level data in T2DM from EDITION 1, 2 and
3 showed that, owing to its favourable PK/PD and 24-hour glucose
profiles,4,5 Gla-300 met the primary endpoint of non-inferiority vs
Gla-100 in terms of glycated haemoglobin (HbA1c) reduction over
6 months, and was consistently associated with less hypoglycaemia.12
After the initial 6-month treatment period, the EDITION 1, 2 and
3 studies included a 6-month extension period, during which participants
continued to receive their previously assigned basal insulin (Gla-300 or
Gla-100).13–15 Here we report the efficacy and safety results from a
patient-level meta-analysis of EDITION 1, 2 and 3, comparing Gla-300
with Gla-100 over the full 12-month treatment period.
2 | RESEARCH DESIGN AND METHODS
2.1 | Study design and participants
EDITION 1, 2 and 3 were multicentre, randomized, open-label, 2-arm,
parallel-group, treat-to-target phase IIIa studies (NCT01499082,
NCT01499095, NCT01676220), the details of which have been previ-
ously described.6,9,11 In brief, the studies included a 6-month treatment
period and a 6-month extension period. All participants were aged
≥18 years, with a diagnosis of T2DM (according to World Health Orga-
nization criteria).16 In EDITION 1, participants had established basal
insulin therapy with ≥42 U/d of either Gla-100 or NPH insulin, together
with mealtime insulin with or without metformin, for at least 1 year.9 In
EDITION 2, participants had at least 6 months on basal insulin treat-
ment (of ≥42 U/d of either Gla-100 or NPH insulin) in combination with
antihyperglycaemic agents other than insulin (excluding sulphonylureas
for 2 months prior to randomization).11 In EDITION 3, participants had
used antihyperglycaemic agents other than insulin for at least 6 months
prior to screening and were insulin-naïve.6 Exclusion criteria included
HbA1c <7.0 % for all 3 studies, HbA1c >10.0 % for EDITION 1 and
2, and >11.0 % for EDITION 3.6,9,11 The appropriate ethics committees
approved the study protocols and the studies were conducted according
to Good Clinical Practice and the Declaration of Helsinki. All participants
provided written, informed consent.
Although the EDITION 1, 2 and 3 studies were conducted in dif-
ferent populations, the consistent study designs (as described above)
and endpoints (see section 2.3) allowed the pooled analysis to be
performed.
2.2 | Treatment
Participants in all studies were randomized (1:1) to receive once-daily
subcutaneous injections of either Gla-300 (Sanofi; using a modified
SoloSTAR pen-injector in EDITION 1 and 2, and a modified Tactipen
pen-injector in EDITION 3) or Gla-100 (Lantus [Sanofi]; using a
SoloSTAR pen-injector) for a 12-month period.6,9,11 Injections were
to be administered between pre-dinner and bedtime at the same time
each evening for each participant.6,9,11 All participants titrated basal
insulin doses to a fasting self-monitored plasma glucose target of 4.4
to 5.6 mmol/L (80–100 mg/dL).6,9,11
2.3 | Endpoints of patient-level meta-analysis
A post hoc patient-level meta-analysis of EDITION 1, 2 and 3 was car-
ried out for the following efficacy endpoints: change in HbA1c from
baseline to month 12; proportion of participants with HbA1c <7.0 %
(<53 mmol/mol) at month 12; and change in insulin dose. This analysis
also evaluated composite endpoints, defined as the percentage of par-
ticipants achieving HbA1c targets (HbA1c <7.0 % or <7.5 %, or HbA1c
reduction ≥0.5 %) without any confirmed (≤3.9 mmol/L [≤70 mg/dL]
or <3.0 mmol/L [<54 mg/dL]) or severe hypoglycaemia, or documen-
ted symptomatic (≤3.9 mmol/L [≤70 mg/dL] or <3.0 mmol/L [<54 mg/
dL]) hypoglycaemia, at night (12 AM to 5:59 AM) and at any time
(24 hours) over 12 months of treatment. Safety and tolerability end-
points included the percentages of participants reporting ≥1 hypogly-
caemic event and annualized rates (events per participant-year) of
hypoglycaemic events, based on American Diabetes Association defini-
tions.17 The analysis also evaluated change in body weight and
adverse events.
2.4 | Data analysis and statistics
Change in HbA1c was analysed using a mixed model for repeated
measures. Efficacy endpoints were analysed according to the treat-
ment group assigned at randomization and using the modified
intention-to-treat (mITT) population, defined as all randomized partici-
pants who received at least 1 dose of study drug and had both a
baseline and ≥1 post-baseline assessment. Composite endpoints were
analysed based on a Cochran–Mantel–Haenszel method, stratified by
screening HbA1c (randomization strata: <8.0 and ≥8.0 %).
Safety endpoints were analysed according to the treatment
received and using the safety population, which included all partici-
pants randomized and exposed to ≥1 dose of study drug. Percentage
of participants reporting ≥1 hypoglycaemic event was estimated
using the Cochran–Mantel–Haenszel method. The annualized rate of
hypoglycaemia (events per participant-year) was analysed using an
overdispersed Poisson regression model. Body weight was assessed
using an analysis of covariance (ANCOVA) model, from baseline to
last on-treatment value. Adverse events were analysed descriptively.
3 | RESULTS
3.1 | Study population
The patient-level meta-analysis of the EDITION 1, 2 and 3 T2DM
studies included 2496 participants, of whom 1247 were randomized
to Gla-300 and 1249 were randomized to Gla-100 (Figure S1). The
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mITT population included 1239 and 1235 participants receiving
Gla-300 and Gla-100, respectively. Overall, 1011 participants receiv-
ing Gla-300 (81.1%) and 983 receiving Gla-100 (78.7%) completed
the 12-month on-treatment period. Baseline characteristics from the
individual study populations and the pooled analysis population have
been previously reported.6,9,11,12
3.2 | Glycaemic control
HbA1c was reduced from baseline in both the Gla-300 and Gla-100
groups. Least squares (LS) mean (standard error [s.e.]) change from
baseline to month 12 was −0.91 (0.03) % (−9.95 [0.33] mmol/mol) with
Gla-300 and −0.80 (0.03) % (−8.74 [0.33] mmol/mol) with Gla-100; the
LS mean difference between groups was −0.10% (95% confidence
interval [CI] −0.18 to 0.02) or −1.09 mmol/mol (95% CI −2.01 to
−0.20); P = .0174 (Figure 1).
3.3 | Confirmed (≤3.9 mmol/L [≤70 mg/dL]) or
severe hypoglycaemia
The percentage of participants experiencing ≥1 confirmed
(≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemic event during the
night (12 AM to 5.59 AM) and at any time of day (24 hours) was signifi-
cantly lower with Gla-300 than with Gla-100 over the 12-month
period (Figure 2 and Table S1).
The annualized rate (events per participant-year) of nocturnal (12 AM
to 5.59 AM) confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycae-
mia was significantly lower with Gla-300 than with Gla-100 over the 12-
month treatment period (rate ratio 0.82 [95% CI 0.67 to 0.99]; Figure 2
and Table S1), whereas the annualized rate of confirmed (≤3.9 mmol/L
[≤70 mg/dL]) or severe hypoglycaemia at any time of day (24 hours)
was comparable in the 2 treatment groups over 12 months of treatment
(rate ratio 0.97 [95% CI 0.87 to 1.09]; Figure 2 and Table S1).
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FIGURE 1 HbA1c (mean  s.e.) over the 12-month treatment period (mITT population). LS mean difference analysed using a mixed model for
repeated measures. BL, baseline; M, month; W, week
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FIGURE 2 Percentage of participants with ≥1 hypoglycaemic event and annualized event rate (events per participant-year) over the 12-month
treatment period (safety population). RR, relative risk for percentage of participants with ≥1 event, rate ratio for annualized event rates
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When analysed by clock time, the percentage of participants with
≥1 confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemic
event, and rates of this category of hypoglycaemia, were numerically
lower with Gla-300 than with Gla-100 during the night and early
morning hours (Figure 3).
3.4 | Other categories of hypoglycaemia
During the 12-month treatment period, a significantly lower percentage
of participants reported ≥1 documented symptomatic (≤3.9 mmol/L
[≤70 mg/dL]) hypoglycaemic event with Gla-300 than with Gla-100 dur-
ing the night (12 AM to 5.59 AM) and at any time of day (24 hours;
Figure 2 and Table S1). The annualized rate of documented symptomatic
(≤3.9 mmol/L [≤70 mg/dL]) hypoglycaemic events over 12 months was
significantly lower for Gla-300 than for Gla-100 during the night (12 AM
to 5.59 AM) and was comparable in the 2 treatments at any time of day
(24 hours; Figure 2 and Table S1).
When considering a more stringent hypoglycaemic threshold
(<3.0 mmol/L [<54 mg/dL]), the percentage of participants experiencing
≥1 confirmed or severe hypoglycaemic event with Gla-300 vs Gla-100
was comparable during the night (12 AM to 5.59 AM) and significantly
lower at any time of day (24 hours; Figure 2 and Table S1). The annual-
ized rate of confirmed (<3.0 mmol/L [<54 mg/dL]) or severe hypogly-
caemia for Gla-300 and Gla-100 was comparable during the night
(12 AM to 5.59 AM) and at any time of day (24 hours) over the 12-month
period (Figure 2 and Table S1). A similar pattern was seen for documen-
ted symptomatic (<3.0 mmol/L [<54 mg/dL]) hypoglycaemia (Figure 2
and Table S1).
3.5 | Severe hypoglycaemia
Severe hypoglycaemia was rare in both treatment groups. The num-
ber of participants with ≥1 severe hypoglycaemic event at any time
of day (24 hours) over 12 months was 40 (3.2%) with Gla-300 and
45 (3.6%) with Gla-100 (Table S1). Annualized rates of severe hypo-
glycaemia were 0.08 events per participant-year in the Gla-300 group
and 0.07 events per participant-year in the Gla-100 group.
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FIGURE 3 Confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia by time of day over the 12-month treatment period. A, Percentage
of participants with ≥1 event and B, annualized event rates (events per participant-year; safety population)
544 RITZEL ET AL.
3.6 | Composite endpoints
Compared with Gla-100-treated participants, a greater percentage of
participants in the Gla-300 group achieved HbA1c targets (HbA1c
<7.0 % or <7.5 % or HbA1c reduction ≥0.5 %) without experiencing
confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia during
the night (12 AM to 5.59 AM; Figure 4 and Table S2). For hypoglycae-
mic events at any time (24 hours) the difference in the percentage of
participants achieving composite endpoints was statistically signifi-
cant for HbA1c reduction ≥0.5 % without confirmed (≤3.9 mmol/L
[≤70 mg/dL]) or severe hypoglycaemia.
When considering other categories of hypoglycaemia, the percent-
age of participants achieving HbA1c targets (HbA1c <7.0 % or <7.5 %
or HbA1c reduction ≥0.5 %) without experiencing a hypoglycaemic
event, both at night and at any time, was either higher or comparable
in the Gla-300 compared with the Gla-100 group (Table S2).
3.7 | Insulin dose
During the 12-month treatment period, the daily basal insulin dose
increased in both treatment groups, but to a greater extent with Gla-300
than Gla-100 (Figure 5). The mean (s.e.) basal insulin dose at 12 months
was 14% higher with Gla-300 than Gla-100 (P < .0001) and averaged
0.89 (0.01) U/kg/d for Gla-300 and 0.78 (0.01) U/kg/d for Gla-100. The
mean (standard deviation [s.d.]) change in daily basal insulin dose from
baseline to month 12 was 0.39 (0.01) U/kg with Gla-300 and 0.27
(0.01) U/kg with Gla-100, and the majority of the increase in insulin dose
(76% for Gla-300 and 81% for Gla-100) occurred during the first
12 weeks (Figure 5).
3.8 | Body weight
Significantly less weight gain was observed for participants treated
with Gla-300 compared with those treated with Gla-100 during the
12-month period (Figure 5; LS mean [s.e.] change 0.85 [0.11] kg and
1.25 [0.11] kg, respectively; LS mean difference between groups
−0.40 kg [95% CI −0.71 to −0.09]; P = .01). The majority of the
between-treatment difference in weight gain occurred during the first
12 weeks (Figure 5).
3.9 | Adverse events
The incidence of adverse events was similar in the 2 treatment
groups (Table S3). Treatment-emergent adverse events (TEAEs) were
reported by 67.7% of participants in the Gla-300 group and 64.0% in
the Gla-100 group. Injection site reactions were reported by 3.0%
of participants in the Gla-300 group and 3.5% of participants in the
Gla-100 group. Treatment-emergent serious adverse events were
reported by 9.5% and 10.5% of participants in the Gla-300 and
Gla-100 groups, respectively. Overall, 29 participants in each group
discontinued treatment owing to a TEAE. Seven participants in the
Gla-300 group and 6 in the Gla-100 group had a TEAE leading to
death; for 1 of these participants (EDITION 2, Gla-300 group) a rela-
tionship between the TEAE (acute myocardial infarction) and the
study medication could not be excluded.
4 | DISCUSSION
Newer basal insulins, such as Gla-300, have been developed to over-
come the limitations of older insulin preparations in terms of stability
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FIGURE 4 Percentage of participants achieving HbA1c targets (HbA1c <7.0 % or <7.5 % or HbA1c reduction ≥0.5 %) at month 12 without
confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia over 12 months of treatment (mITT population). RR, relative risk
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of PK/PD profiles and duration of action. In this 1-year patient-level
meta-analysis of EDITION 1, 2 and 3, including a broad population of
people with T2DM, use of Gla-300 resulted in a HbA1c reduction
that was better sustained over 12 months than that achieved with
use of Gla-100, and was accompanied by a lower risk of confirmed
(≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia during the night
(12 AM to 5.59 AM) and at any time of day (24 hours). Weight gain
was significantly less with Gla-300 than with Gla-100. The present
meta-analysis also showed that the percentage of patients reaching
HbA1c < 7.0 % without confirmed (≤3.9 mmol/L [≤70 mg/dL]) or
severe hypoglycaemia at night was higher with Gla-300 vs Gla-100.
Consistent with the well-established safety profile of Gla-100, and
the comparable metabolic profile of Gla-300 and Gla-100,18 no new
safety signals were identified in this 12-month meta-analysis, and
adverse event profiles were comparable in the 2 treatment groups.
As reported for 6-month data,12 the results from this 1-year
patient-level meta-analysis of EDITION 1, 2 and 3 showed that
HbA1c was reduced with both Gla-300 and Gla-100. When
assessed over a longer follow-up period in the present analysis,
however, Gla-300 was associated with more sustained HbA1c
reduction compared with Gla-100. It remains unknown from the
present data whether this result is partially attributable to the
slightly higher Gla-300 insulin dose, or whether other mechanisms
are also involved. It is interesting that while the differences in
HbA1c levels between Gla-300 and Gla-100 at 12 months were small
in the individual EDITION studies (EDITION 1, −0.17 %; EDITION
2, −0.06 %; EDITION 3, −0.08 %),14,15 they were greatest for EDITION
1, in which participants combined Gla-300 or Gla-100 with mealtime
insulin. In EDITION 1, the improved hypoglycaemia profile of Gla-300
vs Gla-100 may have enabled the participants to make more appropri-
ate decisions regarding the adjustment of their basal and mealtime
insulin doses as duration of treatment increased.14
As observed in the meta-analysis of 6-month data,12 the percent-
age of participants with ≥1 hypoglycaemic event that was confirmed
(≤3.9 mmol/L [≤70 mg/dL]) or severe, or documented symptomatic
(≤3.9 mmol/L [≤70 mg/dL]), was significantly lower with Gla-300
than with Gla-100 over 12 months of treatment, both at night (12 AM
to 5.59 AM) and at any time (24 hours). The annualized rates using
these definitions of nocturnal hypoglycaemia were also significantly
lower with Gla-300 vs Gla-100 over the 12-month treatment period;
however, unlike the 6-month results, the between-group difference
in annualized rate of anytime events was no longer significant over
12 months. One explanation may be that the anytime hypoglycaemia
benefit of Gla-300 vs Gla-100 may be more difficult to demonstrate
when rates of hypoglycaemia are reduced, after the initial dose-
titration period has passed and the daily insulin dose has stabilized.
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This was previously observed in people treated with glargine com-
pared with people treated with NPH insulin added to metformin, with
an initial HbA1c of ~9.5 % (80 mmol/mol).19 Another explanation
may be related to the evening injection time of basal insulin in the
majority of patients in the EDITION programme. The more stable
PK/PD characteristics of Gla-300 vs Gla-100 explain the lower rates
of subsequent nocturnal hypoglycaemia; however, the longer dura-
tion of action of Gla-300, while overcoming any lack of control expe-
rienced by people on Gla-100 in the late afternoon or early evening
prior to the next basal insulin injection, may also result in slightly
more hypoglycaemia at this time (this is supported by the data pre-
sented in Figure 3, although it should be noted that participants in
EDITION 1 were also taking mealtime insulin). During the 6-month
extension period of the EDITION trials, with less overall glycaemic
exposure compared with the first 6-month period as evidenced by
the HbA1c levels shown in Figure 1, this effect may be more promi-
nent and selectively influence rates of anytime but not nocturnal
hypoglycaemia.
The management of T2DM aims to achieve an optimal balance
between glycaemic control and hypoglycaemia. In this regard, it is
interesting to evaluate endpoints that encapsulate both of these
aspects. This patient-level meta-analysis of EDITION 1, 2 and
3 showed that, over 12 months of treatment, a consistently higher
percentage of participants achieved HbA1c targets (HbA1c <7.0 %,
HbA1c <7.5 % and HbA1c reduction ≥0.5 %) without experiencing
confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia in
the Gla-300 group than in the Gla-100 group, although the between-
treatment differences were relatively small. As fear of hypoglycaemia
can be a barrier to optimal insulin therapy,20,21 and can impede gly-
caemic management,2 this finding indicates that Gla-300 has the
potential to confer greater clinical benefits than Gla-100 when used
in clinical practice. However, when interpreting the results of this
composite endpoint analysis it is worth noting that while HbA1c rep-
resents glycaemic control in the ~3 months prior to the 12-month
time point, hypoglycaemia data were collected over the full 12-month
period.
Consistent with findings over 6 months,12 the reduced risk and
rates of nocturnal hypoglycaemia with Gla-300 vs Gla-100 also con-
tinued to extend beyond the protocol-defined nocturnal period
(12 AM to 5.59 AM) and into the daytime. Although hypoglycaemic
events occurring after waking may not inspire the level of fear of
hypoglycaemia while asleep, such events are still clinically relevant.
Basal insulin dose increased in both treatment groups over
12 months of treatment, with the majority of the increase occurring
during the first 12 weeks and very little change apparent thereafter.
The increase in dose was seen to a greater extent with Gla-300 than
Gla-100. As previously discussed,12 this difference between groups
may be the result of increased residence time of Gla-300 in the sub-
cutaneous depot, thereby leading to longer exposure to tissue pepti-
dases. Consequently, after subcutaneous injection the bioavailability
of Gla-300 from the injection site is slightly lower compared with
Gla-100. Regardless, the higher basal insulin dose with Gla-300 did
not adversely impact either hypoglycaemia or body weight; in
fact, both hypoglycaemia risk and body weight gain were lower in the
Gla-300 group than in the Gla-100 group.
A limitation of the present meta-analysis is the open-label nature
of the individual studies, and that the meta-analysis of the 12-month
data from the 3 studies was not pre-planned. Another limitation is
pooling data from studies including people with different disease
stages and treatments, as this may obscure differences attributable to
effects of therapy in particular subgroups of people.
In conclusion, in a large and broad population of people with
T2DM, Gla-300 was associated with more sustained glycaemic
control, and with a lower risk of hypoglycaemia at night and at any
time of day over 12 months of treatment, compared with Gla-100.
The ongoing large-scale real-life, randomized, pragmatic studies of
Gla-300 vs Gla-10022–24 may provide more evidence about the
benefits of Gla-300 in clinical practice.
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